Centre National De La Recherche Scientifique

Centre Leon Berard

The Buck Institute for Age Research

Centre National De La Recherche Scientifique-Cnrs

Patrick Mehlen

Dale E Bredesen

Veronica Galvan

Agnes Bernet

Filipe Calheiros-Lourenco

Julien Fitamant

Agnès Bernet

The subject matter of the present invention relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compound to interact with netrin-1 receptor and/or to inhibit the dimerization of the intracellular domain of the netrin-1 receptor expressed in tumor cells. The invention also relates to a method for predicting the presence of metastatic or aggressive cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of netrin-1. The invention further comprises kits and compounds as a medicament for the treatment of cancer such as metastatic breast cancer, related to the overexpression of netrin-1 by the tumor cells.

Screening for anti-cancer compounds using netrin-1 activity

The invention provides methods and compositions for reducing or inhibiting net beta-amyloid peptide production and/or amyloid plaque formation. The methods and compositions involve administering a netrin-1 polypeptide or netrin-1 therapeutic to a subject in need thereof.

Compositions and methods for suppression of amyloid plaque formation associated with neurodegenerative disorders

Growing community of inventors

Serezin du Rhone, France

Patrick Mehlen